English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 8 September 2020, 15:52 HKT/SGT

Source: Aptorum Group Limited
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10

HONG KONG, Sept 8, 2020 - (ACN Newswire) - Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance, today announced President and Executive Director, Mr. Darren Lui, will share insight into the company's recent developments and upcoming milestones at an investor webinar and the Wall Street Investor Forum on Thursday, September 10, 2020. The details are as follows:

Investor Webinar and Q&A session
Date: Thursday, September 10, 2020
Time: 4:00 PM Eastern Time
To participate in the webinar, please register at:

Questions can be pre-submitted to [email protected] or online during the event.
The Wall Street Investor Forum
Date: Thursday, September 10, 2020
Time: 1:00 PM Eastern Time
To listen to Aptorum Group's presentation, please register at

About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, we are also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. We also have projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates" "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorite des Marches Financiers visa n20-352 on 16 July 2020.

As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n2019/980 of 14 March 2019 and n2019/979 of 14 March 2019.

This press release is provided "as is" without any representation or warranty of any kind.

Investor relations
Aptorum Group Limited
Investor Relations Department:
Tel: +44 020 80929299
Email: [email protected]

Redchip - Financial Communications United States
Investor relations
Craig Brelsford
[email protected]
+1 407 571 0902

Actifin - Financial Communications Europe
Investor relations
Ghislaine Gasparetto
[email protected]
+33 1 56 88 11 22

Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Aptorum Group Limited Releated News
Sept 29, 2020 18:36 HKT/SGT
知臨集團開設傳染病液體活檢初創子公司,獨家獲得了新加坡Accelerate Technologies的許可以共同開發基於基因組分析以追蹤病原體基因組的快速分子病原體診斷技術
Sept 29, 2020 18:35 HKT/SGT
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary, Announces Exclusive In-license from Singapore-based Accelerate Technologies to Co-Develop Molecular Based Rapid Pathogen Diagnostics to Track Pathogenic Genome
Sept 8, 2020 15:46 HKT/SGT
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
Sept 1, 2020 16:41 HKT/SGT
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
Sept 1, 2020 16:32 HKT/SGT
Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575